keyword
MENU ▼
Read by QxMD icon Read
search

Symptom management prostate cancer

keyword
https://www.readbyqxmd.com/read/28794598/dramatic-mixed-response-of-lymphangitic-pulmonary-metastases-in-newly-diagnosed-prostate-cancer
#1
Elan Gorshein, Robin Burger, Anna Ferrari, Tina Mayer
Prostate adenocarcinoma, the most common cancer in males in the United States, is often diagnosed in the nonmetastatic setting. The prognosis with metastatic prostate cancer is less favorable, though treatment options are typically effective in controlling the disease for an extended period. Hormonal therapy is the backbone to the management of prostate cancer metastases, decreasing the level of the prostate-specific antigen and reducing the patient's cancer-related symptoms. Pulmonary metastases, a relatively uncommon initial site of disease involvement, are expected to respond in a similar fashion to hormonal therapy as other organ or bone involvement...
July 2017: Urology Annals
https://www.readbyqxmd.com/read/28747294/patients-perspective-on-participation-in-care-with-or-without-the-support-of-a-smartphone-app-during-radiotherapy-for-prostate-cancer-qualitative-study
#2
Maria Hälleberg Nyman, Catharina Frank, Ann Langius-Eklöf, Karin Blomberg, Kay Sundberg, Yvonne Wengström
BACKGROUND: Patients with prostate cancer are often cared for as outpatients during radiotherapy, which can be an aggravating circumstance for patient participation. There is a need to evaluate whether an interactive smartphone app could enable participation in care, specifically during treatment for prostate cancer. The interactive app (Interaktor) used in this study is developed in codesign with patients and health care professionals; it includes daily reports of symptoms, a risk assessment model, evidence-based self-care advice, along with the provision of immediate access to clinicians...
July 26, 2017: JMIR MHealth and UHealth
https://www.readbyqxmd.com/read/28735014/initial-clinical-experience-with-testosterone-undecanoate-therapy-aveed-%C3%A2-in-testosterone-deficient-men-in-the-united-states
#3
Abraham Morgentaler, Yonah Krakowsky, William Conners, Emily Davidson, Alex Rawji
OBJECTIVE: To report our initial experiences with TU 750mg in testosterone-deficient men. METHODS: All patients receiving TU 750mg at our center between July 1 2014 to August 1 2016 were identified. Clinical response was assessed via structured interviews and laboratory evaluations. Adverse events were documented, including increases in prostate specific antigen (PSA), hematocrit (Hct), and the development of post-injection cough. RESULTS: More than two injections were received by 147 men, with mean age 63...
July 19, 2017: Urology
https://www.readbyqxmd.com/read/28711312/radium-223-in-the-therapeutic-sequence-of-metastatic-castration-resistant-prostate-cancer
#4
M Unda-Urzaiz, R Sousa-Campo, A Rodríguez-Antolín, C Silva-Marins, A Juárez-Soto, B Miñana-López, A Figueiredo-de Castro, J M Cozar-Olmos
CONTEXT: Radium-223 is an □ -particle transmitter with specific action on bone metastases. The Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) study showed that radium-223 extended overall survival and delayed the onset of bone events in patients with symptomatic castration-resistant prostate cancer with bone metastases (mCRPC) and without visceral metastases, with a good safety profile. OBJECTIVE: To review the new scientific evidence on radium-223 based on prespecified and post-hoc analyses of the ALSYMPCA study and on early-access programs after the publication of the ALSYMPCA study, thereby providing new data on the management of patients with mCRPC...
July 12, 2017: Actas Urologicas Españolas
https://www.readbyqxmd.com/read/28700153/-frequent-uro-geriatric-symptoms-helpful-tools-for-general-practitioners
#5
Guillaume Altwegg, Jacques Klein, Grégory Wirth, Christophe E Iselin
Each developed country faces an aging population. Increase of age rises the risk to develop urologic pathology especially in men. Routine investigation and diagnostic of urologic pathology important, however must take into account the patient in his globality (including age, comorbidities, drug medication as well as sociocultural environment). The aim of this article is to help the general practitioner in taking decisions with frequent uro-geriatric symptoms. Bladder catheterization remains an invasive treatment and indication should be regularly re-evaluated...
November 30, 2016: Revue Médicale Suisse
https://www.readbyqxmd.com/read/28676102/effects-of-an-interactive-mhealth-innovation-for-early-detection-of-patient-reported-symptom-distress-with-focus-on-participatory-care-protocol-for-a-study-based-on-prospective-randomised-controlled-trials-in-patients-with-prostate-and-breast-cancer
#6
Ann Langius-Eklöf, Marie-Therése Crafoord, Mats Christiansen, Maria Fjell, Kay Sundberg
BACKGROUND: Cancer patients are predominantly treated as out-patients and as they often experience difficult symptoms and side effects it is important to facilitate and improve patient-clinician communication to support symptom management and self-care. Although the number of projects within supportive cancer care evaluating mobile health is increasing, few evidence-based interventions are described in the literature and thus there is a need for good quality clinical studies with a randomised design and sufficient power to guide future implementations...
July 4, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28655021/the-diagnosis-and-treatment-of-prostate-cancer-a-review
#7
REVIEW
Mark S Litwin, Hung-Jui Tan
Importance: Prostate cancer is the most common cancer diagnosis made in men with more than 160 000 new cases each year in the United States. Although it often has an indolent course, prostate cancer remains the third-leading cause of cancer death in men. Observations: When prostate cancer is suspected, tissue biopsy remains the standard of care for diagnosis. However, the identification and characterization of the disease have become increasingly precise through improved risk stratification and advances in magnetic resonance and functional imaging, as well as from the emergence of biomarkers...
June 27, 2017: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/28619632/enhancing-prostate-cancer-survivorship-care-through-self-management
#8
REVIEW
Ted A Skolarus, Daniela Wittmann, Sarah T Hawley
The lack of clear roles for prostate cancer survivorship care providers places prostate cancer survivors at significant risk of inappropriate use of services delivered piecemeal by different providers, persistent bothersome symptoms, and silent suffering. Optimizing quality of care for prostate cancer survivors hinges on decreasing fragmentation of care, and providing quality symptom management. This is achieved through comprehensive, appropriate medical, surgical, pharmacological and psychosocial care, coupled with self-management, as highlighted in several recent resources addressing long-term and late effects of treatment...
June 13, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28609648/when-no-treatment-is-the-best-treatment-active-surveillance-strategies-for-low-risk-prostate-cancers
#9
REVIEW
V Stavrinides, C C Parker, C M Moore
Although the incidence of prostate cancer is rising due to PSA screening and increased life expectancy, the metastatic potential of low-grade, organ-confined disease remains low. An increasing number of studies suggest that radical treatment in such cases confers little or no survival benefit at a significant cost to morbidity. Active surveillance is a promising management approach of such low-risk cancers: eligible patients are selected based on clinical and pathological findings at diagnosis and are regularly monitored with digital rectal examinations, PSA testing and biopsies...
July 2017: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/28573637/clinical-significance-of-androgen-secretion-disorders-in-men-with-a-malignancy
#10
REVIEW
Pawel J Wiechno, Grazyna M Poniatowska, Wojciech Michalski, Jakub Kucharz, Malgorzata Sadowska, Joanna Jonska-Gmyrek, Karol Nietupski, Joanna Rzymowska, Tomasz Demkow
Cancer and its treatment can lead in men to testosterone deficiency, accompanied by somatic and mental symptoms. Germ cell tumours and their treatment may disturb the pituitary-gonadal axis, hence leading to significant clinical abnormalities. In some prostate cancer patients, castration, temporary or permanent, is a desired therapeutic condition. Yet, it is burdened with various side effects of complex intensity and significance. Last but not least, patients in the terminal stage of a malignancy present with low testosterone concentrations as a part of anorexia-cachexia syndrome...
July 2017: Medical Oncology
https://www.readbyqxmd.com/read/28571827/effect-on-overall-survival-of-locoregional-treatment-in-a-cohort-of-de-novo-metastatic-prostate-cancer-patients-a-single-institution-retrospective-analysis-from-the-royal-marsden-hospital
#11
Diletta Bianchini, David Lorente, Pasquale Rescigno, Zafeiris Zafeiriou, Elena Psychopaida, Hazel O'Sullivan, Mervyn Alaras, Michael Kolinsky, Semini Sumanasuriya, Mariane Sousa Fontes, Joaquin Mateo, Raquel Perez Lopez, Nina Tunariu, Nikolaos Fotiadis, Pardeep Kumar, Alison Tree, Nicholas Van As, Vincent Khoo, Chris Parker, Rosalind Eeles, Alan Thompson, David Dearnaley, Johann S de Bono
BACKGROUND: The optimal management of the primary tumor in metastatic at diagnosis (M1) prostate cancer (PCa) patients is not yet established. We retrospectively evaluated the effect of locoregional treatment (LRT) on overall survival (OS) hypothesizing that this could improve outcome through better local disease control and the induction of an antitumor immune response (abscopal effect). PATIENTS AND METHODS: M1 at diagnosis PCa patients referred to the Prostate Targeted Therapy Group at the Royal Marsden between June 2003 and December 2013 were identified...
April 26, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28562375/exercise-medicine-for-advanced-prostate-cancer
#12
Nicolas H Hart, Daniel A Galvão, Robert U Newton
PURPOSE OF REVIEW: Exercise is a provocative medicine, known for its preventive, complimentary and rehabilitative role in the management of cancer. Impressively, exercise is also emerging as a synergistic and targeted medicine to enhance symptom control, modulate tumour biology and delay disease progression, with the potential to increase overall survival. Given the complex clinical presentation of advanced prostate cancer patients and their omnipresent comorbidities, this review describes the current and potential role of exercise medicine in advanced prostate cancer...
September 2017: Current Opinion in Supportive and Palliative Care
https://www.readbyqxmd.com/read/28541420/surgical-decompression-of-high-grade-spinal-cord-compression-from-hormone-refractory-metastatic-prostate-cancer
#13
Muhammad Omar Chohan, Sweena Kahn, Gustav Cederquist, Anne S Reiner, Joseph Schwab, Ilya Laufer, Mark Bilsky
BACKGROUND: Spine and nonspine skeletal metastases occur in more than 80% of patients with prostate cancer. OBJECTIVE: To examine the characteristics of the patient population undergoing surgery for the treatment of prostate cancer metastatic to the spine. METHODS: A retrospective chart review was performed on all patients treated at our institution from June 1993 to August 2014 for surgical management of metastatic spine disease from prostate cancer...
May 24, 2017: Neurosurgery
https://www.readbyqxmd.com/read/28529549/abiraterone-acetate-and-prednisone-in-chemotherapy-na%C3%A3-ve-prostate-cancer-patients-rationale-evidence-and-clinical-utility
#14
REVIEW
E David Crawford, Neal D Shore, Daniel P Petrylak, Celestia S Higano, Charles J Ryan
Abiraterone acetate 1000 mg/day, combined with prednisone 5 mg PO twice daily, is indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Abiraterone acetate is the oral prodrug of abiraterone, a specific CYP17 inhibitor that blocks androgen biosynthesis within the adrenal glands, testes and tumor microenvironment. In a phase III trial of men with asymptomatic or minimally symptomatic, chemotherapy-naïve mCRPC, treatment with oral abiraterone acetate plus prednisone led to a statistically significant improvement in the co-primary endpoints of overall survival and radiographic progression-free survival when compared with placebo plus prednisone...
May 2017: Therapeutic Advances in Medical Oncology
https://www.readbyqxmd.com/read/28479762/transurethral-resection-of-prostate-in-benign-prostatic-enlargement-with-underactive-bladder-a-retrospective-outcome-analysis
#15
Ashok Kumar Sokhal, Rahul Janak Sinha, Bimalesh Purkait, Vishwajeet Singh
PURPOSE: The purpose of this study was to evaluate the clinical outcome and efficacy of transurethral resection of the prostate in patients of benign prostatic enlargement (BPE) with underactive bladder. MATERIALS AND METHODS: Retrospective study of 174 patients, who underwent transurethral resection of prostate (TURP) between 2008 and 2015, for lower urinary tract symptoms with BPE with bladder underactivity. Clinical history, physical examination, renal function test, urinalysis, cystourethroscopy, transabdominal or transrectal ultrasonography, and urodynamic study were recorded...
April 2017: Urology Annals
https://www.readbyqxmd.com/read/28479477/practice-patterns-in-the-diagnosis-and-management-of-hypogonadism-a-survey-of-sexual-medicine-society-of-north-america-members
#16
Faysal A Yafi, Nora M Haney, James Anaissie, Kenneth J DeLay, Landon Trost, Mohit Khera, Wayne J G Hellstrom
OBJECTIVE: To describe practice patterns in the diagnosis and treatment of hypogonadism, as the optimal approaches are controversial. Multiple therapeutic options are currently available for hypogonadal men and treatment patterns vary considerably. The safety of testosterone therapy (TTh) remains understudied. MATERIALS AND METHODS: A 23-question survey regarding diagnosis and treatment of hypogonadism was sent to all members of the Sexual Medicine Society of North America...
August 2017: Urology
https://www.readbyqxmd.com/read/28462790/contemporary-spinal-oncology-treatment-paradigms-and-outcomes-for-metastatic-tumors-to-the-spine-a-systematic-review-of-breast-prostate-renal-and-lung-metastases
#17
REVIEW
Amy Yao, Christopher A Sarkiss, Travis R Ladner, Arthur L Jenkins
Metastatic spinal disease most frequently arises from carcinomas of the breast, lung, prostate, and kidney. Management of spinal metastases (SpM) is controversial in the literature. Recent studies advocate more aggressive surgical resection than older studies which called for radiation therapy alone, challenging previously held beliefs in conservative therapy. A literature search of the PubMed database was performed for spinal oncology outcome studies published in the English language between 2006 and 2016...
July 2017: Journal of Clinical Neuroscience: Official Journal of the Neurosurgical Society of Australasia
https://www.readbyqxmd.com/read/28434181/management-options-for-biochemically-recurrent-prostate-cancer
#18
REVIEW
Farhad Fakhrejahani, Ravi A Madan, William L Dahut
Prostate cancer is the most common solid tumor malignancy in men worldwide. Treatment with surgery and radiation can be curative in organ-confined disease. Unfortunately, about one third of men develop biochemically recurrent disease based only on rising prostate-specific antigen (PSA) in the absence of visible disease on conventional imaging. For these patients with biochemical recurrent prostate cancer, there is no uniform guideline for subsequent management. Based on available data, it seems prudent that biochemical recurrent prostate cancer should initially be evaluated for salvage radiation or prostatectomy, with curative intent...
May 2017: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/28429147/docetaxel-related-fatigue-in-men-with-metastatic-prostate-cancer-a-descriptive-analysis
#19
A R T Bergin, E Hovey, A Lloyd, G Marx, P Parente, T Rapke, P de Souza
PURPOSE: Fatigue is a prevalent and debilitating side effect of docetaxel chemotherapy in metastatic prostate cancer. A better understanding of the kinetics and nature of docetaxel-related fatigue may provide a framework for intervention. METHODS: This secondary analysis was performed using the MOTIF database, from a phase III, randomised, double-blind, placebo-controlled study of modafinil (200 mg/day for 15 days) for docetaxel-related fatigue in men with metastatic prostate cancer [1]...
September 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/28420419/optimizing-veteran-centered-prostate-cancer-survivorship-care-study-protocol-for-a-randomized-controlled-trial
#20
Ted A Skolarus, Tabitha Metreger, Soohyun Hwang, Hyungjin Myra Kim, Robert L Grubb, Jeffrey R Gingrich, Sarah T Hawley
BACKGROUND: Although prostate cancer is the most common cancer among veterans receiving care in the Veterans Health Administration (VA), more needs to be done to understand and improve survivorship care for this large population. This study, funded by VA Health Services Research & Development (HSR&D), seeks to address the need to improve patient-centered survivorship care for veterans with prostate cancer. METHODS/DESIGN: This is a two-armed randomized controlled trial (RCT) with a target enrollment of up to 325 prostate cancer survivors per study arm (total anticipated n = 600)...
April 18, 2017: Trials
keyword
keyword
3371
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"